Concluding remarks

Given the scarcity of effective treatment options available for patients with advanced melanoma, the dawn of nanoparticle delivery systems could not come at a better time. Future studies in the field should focus on potential combinations of siRNA- and chemotherapeutic/ pharmacological inhibitor-containing nanoparticles because both formulations have been shown to increase delivery and effectivenesss. In addition, although syngeneic mouse models such as B16F10 are highly important in the development of cancer therapies, it would be advantageous to extend these studies into models more relevant to human melanoma progression. Specifically, the recent conditional B-RAF^{V600E}/PTEN-deficient metastatic melanoma mouse is an ideal disease model for preclinical studies of these nanoparticles (Dankort *et al.*, 2009). Additional studies with human melanoma xenograft mice, which allow for representation of a wide range of melanoma genetic backgrounds and staging, would also be of value.

In conclusion, increasing evidence from the past several years has revealed nanoparticles to have the potential to improve the efficacy of current treatments and/or to open doors to strategies such as siRNA targeting, which until now have been plagued with problems. The work of Chen *et al.* (2010) extends this area of research and demonstrates that targeting melanoma tumor cells with c-*Myc* siRNA packaged within the new DSAA nanoparticle, alone or in combination with chemotherapy, can inhibit melanoma tumor growth in several systems, offering hope for the development of potent and efficacious treatment strategies for advanced melanoma.

CONFLICT OF INTEREST
The authors state no conflict of interest.

REFERENCES
Basu S, Harfouche R, Soni S *et al.* (2009) Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. *Proc Natl Acad Sci USA* 106:7957–61

Chen Y, Bathula SR, Yang Q *et al.* (2010) Target nanoparticles deliver siRNA to melanoma. *J Invest Dermatol* 130:2790–8

Dankort D, Curley DP, Cartlidge RA *et al.* (2009) Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet* 41:544–52

Flaherty K, Puzanov I, Sosman J *et al.* (2009) Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. *J Clin Oncol* 27: 15S (Abstract 9000)

Hodi FS, O'Day SJ, McDermott DF *et al.* (2010) Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 363:711–23

Mannava S, GrachtchoukV, Wheeler LJ *et al.* (2008) Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. *Cell Cycle* 7:2392–400

Ross DA, Wilson GD (1998) Expression of c-*Myc* oncoprotein represents a new prognostic marker in cutaneous melanoma. *Br J Surg* 85:46–51

Tran MA, Gowda R, Sharma A *et al.* (2008) Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. *Cancer Res* 68:7638–49

Villares GJ, Zigler M, Wang H *et al.* (2008) Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. *Cancer Res* 68:9078–86

Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA *et al.* (2009) WT1 gene silencing by aerosol delivery of PEI–RNAi complexes inhibits B16-F10 lung metastases growth. *Cancer Gene Ther* 16:892–9

Zhuang D, Mannava S, Grachtchouk V *et al.* (2008) C-Myc overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. *Oncogene* 27:6623–34

Oxygenation State as a Driver of Myofibroblast Differentiation and Wound Contraction: Hypoxia Impairs Wound Closure

Chandan K. Sen[1] and Sashwati Roy[1]

Myofibroblasts are ubiquitous in the human body and may form from the differentiation of fibroblasts, epithelial cells, endothelial cells, and mononuclear cells, among others. Their clinical significance could be substantial, depending on biomedical context. Myofibroblasts help contract open skin wounds, but they could also be key drivers of fibrosis across numerous tissue systems and support tumor invasiveness. Understanding the molecular events underlying myofibroblast formation is significant for many human diseases. In this issue, Modarressi *et al.* address the significance of wound tissue hypoxia in impairing wound contraction by compromising myofibroblast formation. They present compelling evidence indicating tissue hypoxia conflicts with wound closure. We are reminded that correcting wound tissue hypoxia is critical for the tissue's response to other therapeutic interventions.

In 1977, Packer reported that human diploid fibroblasts grown at 10% O_2 live longer than cells grown at the routine 20% O_2 (Packer and Fuehr, 1977). The field of cellular senescence was in its infancy, with the concept of the "Hayflick limit" reported in 1961. In 2003, Roy *et al.* (2003a) reported that growth arrest of fibroblasts caused by 20% O_2 was reversible, consistent with the current study (Modarressi *et al.*, 2010), and it was therefore concluded that exposure of cells to hyperoxic insult causes differentiation, but not senescence. Although it is standard practice to culture cells at an ambient O_2 concentration of 20% (i.e.,

[1]*Comprehensive Wound Center, Davis Heart & Lung Research Institute, Department of Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA*

Correspondence: Chandan K. Sen, 512 Davis Heart & Lung Research Institute, The Ohio State University Medical Center, 473 West 12th Avenue, Columbus, Ohio 43210, USA. E-mail: Chandan.Sen@osumc.edu

room air balanced with 5% CO_2), which corresponds to a pO_2 of approximately 140 mm Hg at sea level, cells within the human body are exposed to much lower concentrations, ranging from about 14% (100 mm Hg) in pulmonary alveoli to 3–5% (35 mm Hg) in the heart and skin (Roy et al., 2003a; Sen et al., 2006). Thus, it is important to recognize that standard cell culture under conditions of 20% O_2 represents exposure of cells to potentially hyperoxic insult, particularly for primary cells that have been freshly isolated from organs and adjusted to lower pO_2 as their physiological normoxic status (Roy et al., 2003a; Sen et al., 2006). For cell lines cultured at 20% O_2 over a long period of time, it is reasonable to assume that the overall cell population represents a hyperoxia-tolerant variety that has survived hyperoxic insult over time by accepting 20% O_2 as a normoxic state. Although 20% O_2 then is normoxia for these cells, it is important to appreciate that this state may little resemble the state of cells or cellular responses in vivo.

How do cells alter their normoxic set point? Cellular O_2 sensing enables physiological adjustments to variations in tissue pO_2. Under basal conditions, cells are adjusted to an O_2 environment biologically read as normoxia (Khanna et al., 2006). A sharp departure from that state triggers an O_2-sensitive biological response. The stabilization of hypoxia-inducible factor (HIF) signifies a robust biological readout of hypoxia. In the presence of sufficient O_2, HIF is hydroxylated and degraded. HIF prolyl hydroxylation is catalyzed by prolyl hydroxylase (PHD) isoenzymes PHD1, -2, and -3. Using cells stably transfected with an HIF reporter construct, the hypothesis that biological cells are capable of resetting their normoxic set point by O_2-sensitive changes in PHD expression has been tested (Khanna et al., 2006). Exposure of a cell line adjusted to growing in 20% O_2 to 5% O_2 resulted in HIF-driven transactivation. However, the same cells adjusted to growing in 5% O_2 did not report hypoxia as read by HIF transactivation.

Notably, cells adjusted to growing in 30% O_2 reported hypoxia when acutely exposed to room air (20% O_2) culture conditions. When grown under elevated O_2 conditions, cells reset their normoxic set point upward by downregulating the expression of PHDs. When grown under low O_2 conditions, cells reset their normoxic set point downward by inducing the expression of PHDs. Exposure of mice in vivo to a hypoxic 10% O_2 environment lowered blood and brain pO_2. Such hypoxic exposure induced PHDs. Exposure of mice to a hyperoxic 50% O_2 ambience repressed the expression of PHD1–3, indicating that O_2-sensitive regulation of PHD expression is also effective in vivo. Studies employing knockdown of PHD expression reveal that O_2-sensitive regulation of PHD may contribute to tuning the normoxic set point in biological cells (Khanna et al., 2006).

> Correction of wound hypoxia is required before tissues can respond to therapeutic interventions.

The state of tissue oxygenation is a major microenvironmental cue that is read by cells, integrated with other microenvironmental cues as a tissue responds to an extracellular signal. Although hypoxia has been studied extensively in the context of cell signaling, hyperoxia has been studied mostly in the context of oxygen toxicity. Both in vitro and in vivo studies with fibroblasts have revealed that hyperoxia may be a potent inducer of myofibroblast differentiation by turning on specific cell signaling events (Kuhn et al., 2007; Roy et al., 2003a,b, 2007, 2010; Sen et al., 2006). In fibroblasts, hyperoxic insult causes growth arrest at the G2/M phase. This arrest is accompanied by induced expression of vimentin and α-smooth muscle actin, as well as by increased cellular contractility in a collagen matrix (Roy et al., 2003a). Hyperoxia also enhances the stability of both Acta2 transcript and α-smooth muscle actin protein (Roy et al., 2007). The morphological/cytoskeletal characteristics of fibroblasts observed in response to hyperoxic exposure match those of fibroblasts cultured at normoxia but treated with transforming growth factor β1 (TGF-β1), a classical inducer of fibroblast differentiation to myofibroblasts.

Interestingly, both hyperoxia and TGF-β signal through p38MAPK to cause fibroblast differentiation (Roy et al., 2003a). In addition, TGF-β activation may be caused by hyperoxia-induced oxidation of the latency-associated peptide. Thus, hyperoxia may not only signal through the TGF-β pathway but also accentuate TGF-β signaling. Recent studies further support this relationship by demonstrating that in fibroblasts all three isoforms of TGF-β are induced by hyperoxia (Roy et al., 2010). Deletion of any one or both of the activating protein-1 (AP-1) binding sites in the TGF-β reporter construct results in a loss of O_2 sensitivity, demonstrating that AP-1 confers O_2 sensitivity to TGF-β transcription. Fos-related AP-1 transcription factor (Fra-2) and apoptosis signal-regulating kinase-1 (Ask-1) have been identified as key mediators of AP-1-dependent hyperoxia-sensitive TGF-β transcription. Knockdown of Fra-2 significantly blunted hyperoxia-induced expression of TGF-β1 as well as TGF-β3 in fibroblasts (Roy et al., 2010). Knockdown of Ask-1 blunted hyperoxia-induced Fra-2 gene expression and nuclear localization in fibroblasts. These observations point toward a central role of Ask-1 and Fra-2 in hyperoxia-inducible AP-1 activation and induction of TGF-β.

Transcriptome-wide profiling studies have identified hyperoxia-sensitive genes in fibroblasts and clustered them into functional groups (Roy et al., 2003b). The p21–p53 axis has emerged as a key hyperoxia-inducible pathway in fibroblasts. Both p21 deficiency and knockdown blunt hyperoxia-induced Acta2 and smooth muscle actin expression. In vivo, reoxygenation-induced upregulation of Acta2 is abrogated completely in p21-deficient mice. Strikingly, overexpression of p21 alone induces differentiation of fibroblasts markedly under normoxic basal conditions. Overexpression of p21 alone induced transcription of α-smooth muscle actin by downregulating YB1 independent of TGF-β1. Thus, studies aimed at understanding the significance of O_2 tension have discovered p21 as a key signaling mediator that regulates the differentiation of fibroblasts to myofibroblasts (Roy et al., 2003a, 2010).

The observations of Modarressi et al. (2010, this issue) establish a key role for

O_2 tension in driving wound contraction. A crucial contribution of this work is the demonstration that under hypoxic conditions compromised myofibroblast contraction is preceded by α-smooth muscle actin disassembly from stress fibers. Consistent with previous reports that the effects of changing O_2 tension on fibroblast differentiation are reversible (Roy et al., 2003a), Modarressi et al. demonstrate that the negative effects of hypoxia on fibroblast differentiation may be corrected by restoring normoxia. Interestingly, Modarressi et al. (2010) identify a facilitatory effect of mechanical stimulation in driving fibroblast differentiation; this effect was most pronounced under conditions of high oxygenation. This observation is relevant to negative pressure wound therapy, which involves mechanical stimulation and during which improved tissue oxygenation is followed by improved wound closure (Vikatmaa et al., 2008).

The wound literature is often confusing in terms of the net impact of hypoxia on wound closure (Sen, 2009). The abundance of literature (primarily related to tumor biology) demonstrating that hypoxia is a cue for angiogenesis has led many to erroneously conclude that hypoxia may be helpful for cutaneous wound healing. However, from a clinical standpoint we know that this is unlikely, because ischemic wounds are clearly hypoxic, yet refractory to closure. Acutely, hypoxia may help generate growth and repair factors necessary to lay the foundation for wound closure. However, unless there is sufficient oxygen (Sen, 2009), a good foundation for healing will not lead to closure. HIF-dependent hypoxia-inducible microRNA miR210 impairs wound epithelialization, a key aspect of overall wound closure (Biswas et al., 2010). Therefore, although stabilization of HIF may elicit angiogenic responses, the ultimate effect is to oppose wound closure by stalling wound re-epithelialization. The work by Modarressi et al. (2010) represents an important contribution to the field of wound healing, in which compelling evidence supports tissue hypoxia's conflict with wound closure. We are reminded that correction of wound tissue hypoxia is critical for wound tissue to respond to other therapeutic interventions.

REFERENCES

Biswas S, Roy S, Banerjee J et al. (2010) Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA 107:6976–81

Khanna S, Roy S, Maurer M et al. (2006) Oxygen-sensitive reset of hypoxia-inducible factor transactivation response: prolyl hydroxylases tune the biological normoxic set point. Free Radic Biol Med 40:2147–54

Kuhn DE, Roy S, Radtke J et al. (2007) Laser microdissection and capture of pure cardiomyocytes and fibroblasts from infarcted heart regions: perceived hyperoxia induces p21 in peri-infarct myocytes. Am J Physiol Heart Circ Physiol 292:H1245–53

Modarressi A, Pietramaggiori G, Godbout C et al. (2010) Hypoxia impairs skin myofibroblast differentiation and function. J Invest Dermatol 130:2818–27

Packer L, Fuehr K (1977) Low oxygen concentration extends the lifespan of cultured human diploid cells. Nature 267:423–5

Roy S, Khanna S, Bickerstaff AA et al. (2003a) Oxygen sensing by primary cardiac fibroblasts: a key role of p21(Waf1/Cip1/Sdi1). Circ Res 92:264–71

Roy S, Khanna S, Wallace WA et al. (2003b) Characterization of perceived hyperoxia in isolated primary cardiac fibroblasts and in the reoxygenated heart. J Biol Chem 278:47129–35

Roy S, Khanna S, Rink T et al. (2007) P21waf1/cip1/sdi1 as a central regulator of inducible smooth muscle actin expression and differentiation of cardiac fibroblasts to myofibroblasts. Mol Biol Cell 18:4837–46

Roy S, Khanna S, Azad A et al. (2010) Fra-2 mediates oxygen-sensitive induction of transforming growth factor beta in cardiac fibroblasts. Cardiovasc Res 87:647–55

Sen CK (2009) Wound healing essentials: let there be oxygen. Wound Repair Regen 17:1–18

Sen CK, Khanna S, Roy S (2006) Perceived hyperoxia: oxygen-induced remodeling of the reoxygenated heart. Cardiovasc Res 71:280–8

Vikatmaa P, Juutilainen V, Kuukasjarvi P et al. (2008) Negative pressure wound therapy: a systematic review on effectiveness and safety. Eur J Vasc Endovasc Surg 36:438–48

Lucky Number Seven: RNase 7 Can Prevent *Staphylococcus aureus* Skin Colonization

John S. Cho[1], Caiyun Xuan[1] and Lloyd S. Miller[1]

Staphylococcus aureus colonization is a major risk factor for infection. In this issue, Simanski *et al.* demonstrate that the antimicrobial peptide RNase 7 is essential for preventing *S. aureus* colonization in human skin. These findings suggest that therapeutic interventions aimed at targeting RNase 7 production in the skin may be a novel strategy to protect against *S. aureus* infections.

Antimicrobial peptides and skin host defense

Human skin presents both a physical and an immunological barrier against invading microbial pathogens. In addition to contributing to the physical barrier, the stratum corneum contains antimicrobial peptides that act as a first line of defense against pathogenic microbial colonization and infection by pathogens such as bacteria, fungi, and viruses (Lai and Gallo, 2009).

[1]Division of Dermatology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Correspondence: Lloyd S. Miller, Division of Dermatology, University of California, Los Angeles, 52-121 Center for Health Sciences, 10833 Le Conte Avenue, Los Angeles, California 90095, USA.
E-mail: lloydmiller@mednet.ucla.edu